TABLE OF CONTENTS
Volume 22, Issue 12 (December 2008)
Review
Etiology of common childhood acute lymphoblastic leukemia: the adrenal hypothesis
K Schmiegelow, T Vestergaard, S M Nielsen and H Hjalgrim
Leukemia 22: 2137-2141; advance online publication, August 21, 2008; doi:10.1038/leu.2008.212
Original Articles
Acute Leukemias
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study
K Nguyen, M Devidas, S-C Cheng, M La, E A Raetz, W L Carroll, N J Winick, S P Hunger, P S Gaynon and M L Loh for the Children's Oncology Group
Leukemia 22: 2142-2150; advance online publication, September 25, 2008; doi:10.1038/leu.2008.251
The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation
S Tavor, M Eisenbach, J Jacob-Hirsch, T Golan, I Petit, K BenZion, S Kay, S Baron, N Amariglio, V Deutsch, E Naparstek and G Rechavi
Leukemia 22: 2151-5158; advance online publication, September 4, 2008; doi:10.1038/leu.2008.238
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells
C Nishioka, T Ikezoe, J Yang, H P Koeffler and A Yokoyama
Leukemia 22: 2159-2168; advance online publication, September 11, 2008; doi:10.1038/leu.2008.243
Chronic Myeloproliferative Disorders
SOCS2: inhibitor of JAK2V617F-mediated signal transduction
H Quentmeier, R Geffers, E Jost, R A F MacLeod, S Nagel, S Röhrs, J Romani, M Scherr, M Zaborski and H G Drexler
Leukemia 22: 2169-2175; advance online publication, September 4, 2008; doi:10.1038/leu.2008.226
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
J Cortes, D-W Kim, E Raffoux, G Martinelli, E Ritchie, L Roy, S Coutre, S Corm, N Hamerschlak, J-L Tang, A Hochhaus, H J Khoury, T H Brümmendorf, M Michallet, G Rege-Cambrin, C Gambacorti-Passerini, J P Radich, T Ernst, C Zhu, J M A Van Tornout and M Talpaz
Leukemia 22: 2176-2183; advance online publication, August 28, 2008; doi:10.1038/leu.2008.221
Chronic Lymphocytic Leukemia
Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia
J B Weinberg, A D Volkheimer, M Mihovilovic, N Jiang, Y Chen, K Bond, J O Moore, J P Gockerman, L F Diehl, C M de Castro, D A Rizzieri, M C Levesque, R DeKroon and W J Strittmatter
Leukemia 22: 2184-2192; advance online publication, September 11, 2008; doi:10.1038/leu.2008.241
Minimal Residual Disease
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia
M Paganin, M Zecca, G Fabbri, K Polato, A Biondi, C Rizzari, F Locatelli and G Basso
Leukemia 22: 2193-2200; advance online publication, August 28, 2008; doi:10.1038/leu.2008.227
Immunology
Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood CD4+ T cells
M L Lesniewski, P Haviernik, R P Weitzel, S Kadereit, M M Kozik, L R Fanning, Y C Yang, Y Hegerfeldt, M R Finney, M Z Ratajczak, N Greco, P Paul, J Maciejewski and M J Laughlin
Leukemia 22: 2201-2207; advance online publication, September 4, 2008; doi:10.1038/leu.2008.234
Oncogenes, Fusion Genes and Tumor Suppressor Genes
Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases
K De Keersmaecker, M Versele, J Cools, G Superti-Furga and O Hantschel
Leukemia 22: 2208-2216; advance online publication, September 11, 2008; doi:10.1038/leu.2008.242
Transcriptional Control and Signal Transduction
ICER expression inhibits leukemia phenotype and controls tumor progression
M Pigazzi, E Manara, E Baron and G Basso
Leukemia 22: 2217-2225; advance online publication, September 11, 2008; doi:10.1038/leu.2008.244
Lymphoma
Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
W Klapper, H Stoecklein, S Zeynalova, G Ott, F Kosari, A Rosenwald, M Loeffler, L Trümper, M Pfreundschuh and Reiner Siebert
Leukemia 22: 2226-2229; advance online publication, August 28, 2008; doi:10.1038/leu.2008.230
Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome
T Krejsgaard, L M Gjerdrum, E Ralfkiaer, B Lauenborg, K W Eriksen, A-M Mathiesen, L F Bovin, R Gniadecki, C Geisler, L P Ryder, Q Zhang, M A Wasik, N Ødum and A Woetmann
Leukemia 22: 2230-2239; advance online publication, September 4, 2008; doi:10.1038/leu.2008.224
Myeloma
A role for IFN-
1 in multiple myeloma B cell growth
A J Novak, D M Grote, S C Ziesmer, V Rajkumar, S E Doyle and S M Ansell
Leukemia 22: 2240-2246; advance online publication, October 2, 2008; doi:10.1038/leu.2008.263
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
E Terpos, E Kastritis, M Roussou, D Heath, D Christoulas, N Anagnostopoulos, E Eleftherakis-Papaiakovou, K Tsionos, P Croucher and M A Dimopoulos
Leukemia 22: 2247-2256; advance online publication, September 4, 2008; doi:10.1038/leu.2008.235
Letters to the Editor
How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance
T Zenz, S Häbe, T Denzel, D Winkler, H Döhner and S Stilgenbauer
Leukemia 22: 2257-2258; advance online publication, May 15, 2008; doi:10.1038/leu.2008.114
Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set
M J Bishton, R J Hicks, H M Prince, D S Ritchie, M Wolf and J F Seymour
Leukemia 22: 2259-2260; advance online publication, May 15, 2008; doi:10.1038/leu.2008.116
Reply to 'Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independence data set' by Mark J Bishton et al
L F Porrata, K Ristow, T E Witzig, N Tuinistra, T M Habermann, D J Inwards, S M Ansell, I N Micallef, P B Johnston and S N Markovic
Leukemia 22: 2260-2261; advance online publication, May 15, 2008; doi:10.1038/leu.2008.117
Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus
H Deng, N Tang, A E Stief, N Mehta, E Baig, R Head, G Sleep, X-Z Yang, C McKerlie, S Trudel, A K Stewart and J A McCart
Leukemia 22: 2261-2264; advance online publication, May 29, 2008; doi:10.1038/leu.2008.120
Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-
and heavy-chain gene rearrangements
R Sutton, A Y Bahar, E Kwan, J E Giles, N C Venn, S Tran, N Hackenberg, L Dalla Pozza, G M Marshall, M Haber, V H J van der Velden and M D Norris
Leukemia 22: 2265-2267; advance online publication, May 22, 2008; doi:10.1038/leu.2008.121
PKR is activated in MDS patients and its subcellular localization depends on disease severity
M Y Follo, C Finelli, S Mongiorgi, C Clissa, C Bosi, G Martinelli, W L Blalock, L Cocco and A M Martelli
Leukemia 22: 2267-2269; advance online publication, May 22, 2008; doi:10.1038/leu.2008.122
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
A Agarwal, C A Eide, A Harlow, A S Corbin, M J Mauro, B J Druker, C L Corless, M C Heinrich and M W Deininger
Leukemia 22: 2269-2272; advance online publication, May 29, 2008; doi:10.1038/leu.2008.124
Cotransplantation of mesenchymal cells and a higher relapse rate: a role for HLA-G molecules?
R Rizzo, D Campioni, F Lanza and O R Baricordi
Leukemia 22: 2273; advance online publication, June 5, 2008; doi:10.1038/leu.2008.135
Notch inhibition blocks multiple myeloma cell-induced osteoclast activation
R Schwarzer, M Kaiser, O Acikgoez, U Heider, S Mathas, R Preissner, O Sezer, B Doerken and F Jundt
Leukemia 22: 2273-2277; advance online publication, June 5, 2008; doi:10.1038/leu.2008.138
Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy
R Swords, C O'Rafferty, F Giles and P Browne
Leukemia 22: 2277-2278; advance online publication, June 5, 2008; doi:10.1038/leu.2008.139
Novel gain-of-function mutation in the extracellular domain of the PDGFRA gene in infant acute lymphoblastic leukemia with t(4;11)(q21;q23)
M Hiwatari, R Ono, T Taki, A Hishiya, E Ishii, T Kitamura, Y Hayashi and T Nosaka
Leukemia 22: 2279-2280; advance online publication, June 12, 2008; doi:10.1038/leu.2008.140
Clinical and biological significance of RAS mutations in multiple myeloma
W J Chng, N Gonzalez-Paz, T Price-Troska, S Jacobus, S V Rajkumar, M M Oken, R A Kyle, K J Henderson, S Van Wier, P Greipp, B Van Ness and R Fonseca
Leukemia 22: 2280-2284; advance online publication, June 5, 2008; doi:10.1038/leu.2008.142
Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia
B F Goemans, C M Zwaan, S J H Vijverberg, A H Loonen, U Creutzig, K Hählen, D Reinhardt, B E S Gibson, J Cloos and G J L Kaspers
Leukemia 22: 2284-2285; advance online publication, June 19, 2008; doi:10.1038/leu.2008.147
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia
M P Martelli, N Manes, A Liso, V Pettirossi, B Verducci Galletti, B Bigerna, A Pucciarini, M F De Marco, M T Pallotta, N Bolli, M Sborgia, F di Raimondo, F Fabbiano, G Meloni, G Specchia, M F Martelli and B Falini
Leukemia 22: 2285-2288; advance online publication, June 19, 2008; doi:10.1038/leu.2008.149
Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR
O Pelz-Ackermann, M Cross, H Pfeifer, M Deininger, S-Y Wang, H K Al-Ali, D Niederwieser and T Lange
Leukemia 22: 2288-2291; advance online publication, July 10, 2008; doi:10.1038/leu.2008.180
Corrigenda
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis FREE
E Terpos, E Kastritis, M Roussou, D Heath, D Christoulas, N Anagnostopoulos, E Eleftherakis-Papaiakovou, K Tsionos, P Croucher and M A Dimopoulos
Leukemia 22: 2292; doi:10.1038/leu.2008.288
Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood CD4+T cells FREE
M L Lesniewski, P Haviernik, R P Weitzel, S Kadereit, M M Kozik, L R Fanning, Y C Yang, Y Hegerfeldt, M R Finney, M Z Ratajczak, N Greco, P Paul, J Maciejewski and M J Laughlin
Leukemia 22: 2293-2294; doi:10.1038/leu.2008.292
